<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460327</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Modelling the Relative Vaccine Efficacy of ARCT-154, a Self-Amplifying mRNA COVID-19 Vaccine, versus BNT162b2 Using Immunogenicity Data.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1161</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101161</ELocationID><Abstract><AbstractText><b>Background</b>: Self-amplifying mRNA vaccines have the potential to increase the magnitude and duration of protection against COVID-19 by boosting neutralizing antibody titers and cellular responses. <b>Methods</b>: In this study, we used the immunogenicity data from a phase 3 randomized trial comparing the immunogenicity of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, with BNT162b2 mRNA COVID-19 vaccine to estimate the relative vaccine efficacy (rVE) of the two vaccines over time in younger (&lt;60 years) and older (≥60 years) adults. <b>Results</b>: By day 181 post-vaccination, the rVE against symptomatic and severe Wuhan-Hu-1 disease was 9.2-11.0% and 1.2-1.5%, respectively, across age groups whereas the rVE against symptomatic and severe Omicron BA.4/5 disease was 26.8-48.0% and 5.2-9.3%, respectively, across age groups. Sensitivity analysis showed that varying the threshold titer for 50% protection against severe disease up to 10% of convalescent sera revealed incremental benefits of ARCT-154 over BNT162b2, with an rVE of up to 28.0% against Omicron BA.4/5 in adults aged ≥60 year. <b>Conclusions</b>: Overall, the results of this study indicate that ARCT-154 elicits broader and more durable immunogenicity against SARS-CoV-2, translating to enhanced disease protection, particularly for older adults against Omicron BA.4/5.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Van Hung</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>VHN Consulting, 69370 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crépey</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1852-0752</Identifier><AffiliationInfo><Affiliation>RSMS-Inserm U 1309, Arènes-UMR 6051, EHESP, CNRS, IEP Rennes, University of Rennes, 35043 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pivette</LastName><ForeName>Jean Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>VHN Consulting, 22450 Trezeny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Settembre</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3021-4638</Identifier><AffiliationInfo><Affiliation>CSL Seqirus, Waltham, MA 02451, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajaram</LastName><ForeName>Sankarasubramanian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8988-7511</Identifier><AffiliationInfo><Affiliation>CSL Seqirus, Maidenhead SL6 8AA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youhanna</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0008-8153-2223</Identifier><AffiliationInfo><Affiliation>CSL Seqirus, Waltham, MA 02451, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraro</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CSL Seqirus, Waltham, MA 02451, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CSL Seqirus, Waltham, MA 02451, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Boxmeer</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CSL Seqirus, 1105 BJ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mould-Quevedo</LastName><ForeName>Joaquin F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0003-4847-5956</Identifier><AffiliationInfo><Affiliation>CSL Seqirus, Summit, NJ 07901, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>n/a</GrantID><Agency>CSL Seqirus Inc</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARCT-154</Keyword><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">older adults</Keyword><Keyword MajorTopicYN="N">self-amplifying mRNA vaccine</Keyword></KeywordList><CoiStatement>Van Hung Nguyen and Jean Marie Pivette: Employees of VHN Consulting, which received funding from CSL Seqirus for the analysis described in the manuscript and for manuscript development. Pascal Crépey received funding from VHN Consulting for the analysis described in the manuscript. Ethan Settembre, Sankarasubramanian Rajaram, John Youhanna, Aimee Ferraro, Cheng Chang, Josephine van Boxmeer, and Joaquin F. Mould-Quevedo: Employees of CSL Seqirus.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460327</ArticleId><ArticleId IdType="pmc">PMC11511100</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101161</ArticleId><ArticleId IdType="pii">vaccines12101161</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention  Trends in United States COVID-19 Hospitalizations, Deaths, Emergency Department (ED) Visits, and Test Positivity by Geographic Area. Centers for Disease Control and Prevention.  [(accessed on 15 April 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>UKHSA  UKHSA Data Dashboard: COVID-19.  [(accessed on 25 June 2024)]; Available online:  https://ukhsa-dashboard.data.gov.uk/topics/covid-19#healthcare.</Citation></Reference><Reference><Citation>Chakraborty C., Bhattacharya M., Dhama K. SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. Vaccines. 2023;11:682. doi: 10.3390/vaccines11030682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030682</ArticleId><ArticleId IdType="pmc">PMC10054865</ArticleId><ArticleId IdType="pubmed">36992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States.  [(accessed on 12 February 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.</Citation></Reference><Reference><Citation>Brice Y., Morgan L., Kirmani M., Kirmani M., Udeh M.C. COVID-19 Vaccine Evolution and Beyond. Neurosci. Insights. 2023;18:26331055231180543. doi: 10.1177/26331055231180543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/26331055231180543</ArticleId><ArticleId IdType="pmc">PMC10280118</ArticleId><ArticleId IdType="pubmed">37351483</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health  Decades in the Making: mRNA COVID-19 Vaccines.  [(accessed on 7 May 2024)]; Available online:  https://covid19.nih.gov/nih-strategic-response-covid-19/decades-making-mrna-covid-19-vaccines.</Citation></Reference><Reference><Citation>Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Tang T., Chen Y., Huang X., Liang T. mRNA vaccines in disease prevention and treatment. Signal Transduct. Target. Ther. 2023;8:365. doi: 10.1038/s41392-023-01579-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01579-1</ArticleId><ArticleId IdType="pmc">PMC10509165</ArticleId><ArticleId IdType="pubmed">37726283</ArticleId></ArticleIdList></Reference><Reference><Citation>Comes J.D.G., Pijlman G.P., Hick T.A.H. Rise of the RNA machines—Self-amplification in mRNA vaccine design. Trends Biotechnol. 2023;41:1417–1429. doi: 10.1016/j.tibtech.2023.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2023.05.007</ArticleId><ArticleId IdType="pmc">PMC10266560</ArticleId><ArticleId IdType="pubmed">37328401</ArticleId></ArticleIdList></Reference><Reference><Citation>Low J.G., de Alwis R., Chen S., Kalimuddin S., Leong Y.S., Mah T.K.L., Yuen N., Tan H.C., Zhang S.L., Sim J.X.Y., et al. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying COVID-19 mRNA vaccine. NPJ Vaccines. 2022;7:161. doi: 10.1038/s41541-022-00590-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00590-x</ArticleId><ArticleId IdType="pmc">PMC9745278</ArticleId><ArticleId IdType="pubmed">36513697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hồ N.T., Hughes S.G., Ta V.T., Phan L.T., Đỗ Q., Nguyễn T.V., Phạm A.T.V., Thị Ngọc Đặng M., Nguyễn L.V., Trịnh Q.V., et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: Pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat. Commun. 2024;15:4081. doi: 10.1038/s41467-024-47905-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47905-1</ArticleId><ArticleId IdType="pmc">PMC11094049</ArticleId><ArticleId IdType="pubmed">38744844</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda Y., Kumagai Y., Kanai M., Iwama Y., Okura I., Minamida T., Yagi Y., Kurosawa T., Greener B., Zhang Y., et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: A double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect. Dis. 2024;24:351–360. doi: 10.1016/S1473-3099(23)00650-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00650-3</ArticleId><ArticleId IdType="pubmed">38141632</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda Y., Kumagai Y., Kanai M., Iwama Y., Okura I., Minamida T., Yagi Y., Kurosawa T., Chivukula P., Zhang Y., et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2. Lancet Infect. Dis. 2024;24:341–343. doi: 10.1016/S1473-3099(24)00060-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00060-4</ArticleId><ArticleId IdType="pubmed">38310906</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Núñez J.J., Muñoz-Valle J.F., Torres-Hernández P.C., Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines. 2021;9:1376. doi: 10.3390/vaccines9121376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121376</ArticleId><ArticleId IdType="pmc">PMC8706198</ArticleId><ArticleId IdType="pubmed">34960121</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., Astudillo M.G., Yang D., Miller T.E., Feldman J., Hauser B.M., Caradonna T.M., Clayton K.L., Nitido A.D., et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476–488.e411. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle K.A., Ambrosino D.M., Fiore-Gartland A., Goldblatt D., Gilbert P.B., Siber G.R., Dull P., Plotkin S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423–4428. doi: 10.1016/j.vaccine.2021.05.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.063</ArticleId><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Schlub T.E., Cromer D., Steain M., Fong Y., Gilbert P.B., Subbarao K., Triccas J.A., Kent S.J., Davenport M.P. Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg. Infect. Dis. 2023;29:381–388. doi: 10.3201/eid2902.221422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2902.221422</ArticleId><ArticleId IdType="pmc">PMC9881762</ArticleId><ArticleId IdType="pubmed">36692375</ArticleId></ArticleIdList></Reference><Reference><Citation>Almendro-Vázquez P., Laguna-Goya R., Paz-Artal E. Defending against SARS-CoV-2: The T cell perspective. Front. Immunol. 2023;14:1107803. doi: 10.3389/fimmu.2023.1107803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1107803</ArticleId><ArticleId IdType="pmc">PMC9911802</ArticleId><ArticleId IdType="pubmed">36776863</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermens J.M., Kesmir C. Role of T cells in severe COVID-19 disease, protection, and long term immunity. Immunogenetics. 2023;75:295–307. doi: 10.1007/s00251-023-01294-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-023-01294-9</ArticleId><ArticleId IdType="pmc">PMC9905767</ArticleId><ArticleId IdType="pubmed">36752852</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruggi G., Ulmer J.B., Rappuoli R., Yu D. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. Curr. Top. Microbiol. Immunol. 2022;440:31–70. doi: 10.1007/82_2021_233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/82_2021_233</ArticleId><ArticleId IdType="pubmed">33861374</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R., Gan E.S., Chen S., Leong Y.S., Tan H.C., Zhang S.L., Yau C., Low J.G.H., Kalimuddin S., Matsuda D., et al. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol. Ther. 2021;29:1970–1983. doi: 10.1016/j.ymthe.2021.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8019652</ArticleId><ArticleId IdType="pubmed">33823303</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Reynaldi A., Hie A., Schlub T.E., Juno J.A., Wheatley A.K., Kent S.J., Khoury D.S., Davenport M.P. Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates. Nat. Commun. 2024;15:8395. doi: 10.1038/s41467-024-52194-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-52194-9</ArticleId><ArticleId IdType="pmc">PMC11436652</ArticleId><ArticleId IdType="pubmed">39333473</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Saha A., Bhattacharya M., Dhama K., Agoramoorthy G. Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants. Mol. Ther. Nucleic Acids. 2023;31:437–439. doi: 10.1016/j.omtn.2023.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2023.01.013</ArticleId><ArticleId IdType="pmc">PMC9923361</ArticleId><ArticleId IdType="pubmed">36817724</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W., Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182:812–827.e819. doi: 10.1016/j.cell.2020.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y., Huang Y., Benkeser D., Carpp L.N., Áñez G., Woo W., McGarry A., Dunkle L.M., Cho I., Houchens C.R., et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 2023;14:331. doi: 10.1038/s41467-022-35768-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35768-3</ArticleId><ArticleId IdType="pmc">PMC9851580</ArticleId><ArticleId IdType="pubmed">36658109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>